Proton Therapy Market

Proton therapy is a type of radiation therapy that uses high-power energy to treat cancer and certain non-cancerous tumors. Radiation therapy using X-rays has long been used to treat the conditions such as tumor cell or cancer cells. Proton therapy uses energy from positively charged particles (protons). It is used to treat non-cancerous tumors as well as malignancy. Proton therapy must be used to treat the illness, or it must be combined with other treatments like surgery and chemotherapy. If the cancer is still present or returns after conventional X-ray radiation, proton treatment may also be employed. Proton therapy is sometimes used to treat various cancers such as brain tumors, sarcoma, prostate cancer, pediatric cancer, and pancreatic cancer. The therapy utilizes a precision dose of high-energy radiation in the target cancer cells and tumor cells. Increasing funding for cancer research is expected to offer lucrative growth opportunities for market players. Furthermore, the increasing number of healthcare facilities offering proton therapy is also expected to drive market growth.

Market Dynamics

The key market players are focused on adopting growth strategies, such as collaboration and acquisitions, which is anticipated to fuel the global proton therapy market growth. The increasing number of cancer patients and healthcare facilities is expected to boost the market growth. For instance, in August 2022, IBA (Ion Beam Applications), a medical technology company, announced that it had signed a collaboration agreement with Apollo Hospitals Enterprise Ltd (AHEL), a multispecialty health care unit, to provide proton therapy training and education programs for IBA customers in Asia.

Key features of the study:

• This report provides an in-depth analysis of the global proton therapy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

• It profiles key players in the global proton therapy market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Hitachi Ltd., Ion Beam Applications SA, Mevion Medical Systems, Mitsubishi Electric Corporation, Provision Healthcare, ProTom International, Sumitomo Heavy Industries, Varian Medical Systems, Optivus Proton Therapy, Inc., and Advanced Oncotherapy plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global proton therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton therapy market

Detailed Segmentation:

• Global Proton Therapy Market, By Set-up Type:
  • Single Room
  • Multiple Room
• Global Proton Therapy Market, By Indication:
  • Head & Neck Cancer
  • Sarcoma
  • Pediatric Cancer
  • Gastro-intestinal Cancer
  • Prostate Cancer
  • Lung Cancer
• Global Proton Therapy Market, By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles
  • Hitachi Ltd.
  • Ion Beam Applications SA
  • Mevion Medical Systems
  • Mitsubishi Electric Corporation
  • Provision Healthcare
  • Protom International
  • Sumitomo Heavy Industries
  •  Varian Medical Systems
  • Optivus Proton Therapy, Inc.
  • Advanced Oncotherapy plc.